Journals / Türk Psikiyatri Dergisi / 2016 / Cilt: 27 - Sayı: 3

IL-4, TGF-?, NF-?B and MPO levels in Patients with Treatment Resistant Schizophrenia

Tedaviye Dirençli Şizofreni Hastalarında IL-4, TGF-?, NF-?B ve MPO Düzeyleri

Pages
170–175
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The fact that the increase in NF-?B that we found in treatment-resistant schizophrenia patients in this study has also been reported in the first attack in untreated schizophrenia patients in previous studies indicates that NF-?B plays a role in the disorder's physiopathology from the beginning.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Schizophrenia is a chronic psychotic disorder in which genetics and environmental factors such as infection and the corresponding immune response play a role in the etiopathogenesis.
📊
Key Findings & Data:The aim of this study was to compare some immune factors such as nuclear factor-?B (NF-?B) activation, myeloperoxidase (MPO), the antiinflammatory cytokine interleukin-4 (IL-4), and regulatory cytokine transforming growth factor-? (TGF-?) in schizophrenia patients and an age- and gender-matched control group.
💡
Conclusion & Impact:The fact that the increase in NF-?B that we found in treatment-resistant schizophrenia patients in this study has also been reported in the first attack in untreated schizophrenia patients in previous studies indicates that NF-?B plays a role in the disorder's physiopathology from the beginning.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Schizophrenia is a chronic psychotic disorder in which genetics and environmental factors such as infection and the corresponding immune response play a role in the etiopathogenesis. The aim of this study was to compare some immune factors such as nuclear factor-?B (NF-?B) activation, myeloperoxidase (MPO), the antiinflammatory cytokine interleukin-4 (IL-4), and regulatory cytokine transforming growth factor-? (TGF-?) in schizophrenia patients and an age- and gender-matched control group. Method: Plasma levels of IL-4, TGF-?, MPO, and NF-?B activation in 20 subjects with treatment-resistant schizophrenia and 20 age- and gender-matched healthy controls were analyzed. Disease severity was evaluated using the Brief Psychiatric Rating Scale (BPRS).Results: Plasma TGF-? levels were found to be significantly lower and NF-?B to be significantly higher in antipsychotic treatment-resistant schizophrenia patients than in controls in this study. No significant differences were found between the patient and control groups for serum IL-4 and MPO levels.Conclusion: The low TGF-? level in treatment-resistant schizophrenia patients in the symptom exacerbation period indicates that there is inadequate Th1/Th2 balance. Large-scale studies are required to investigate whether this is responsible for resistance in schizophrenia. The fact that the increase in NF-?B that we found in treatment-resistant schizophrenia patients in this study has also been reported in the first attack in untreated schizophrenia patients in previous studies indicates that NF-?B plays a role in the disorder's physiopathology from the beginning.

Özet

Amaç: Şizofreni etiyolojisinde genetik, enfeksiyon ve enfeksiyona immün yanıt gibi çevresel faktörlerin rol oynadığı kronik psikotik bir bozukluktur. Bu çalışmanın amacı nükleer faktör-?B (NF-kB) aktivasyonu, myeloperoksidaz (MPO), antiinflamatuar sitokin interlökin-4 (IL-4) ve regulatuar sitokin transforming growth faktör-? (TGF-?) gibi bazı immün faktörleri şizofreni hastalarında ve yaş ve cinsiyet olarak eşleştirilmiş kontrol grubunda karşılaştırmaktır. Yöntem: Tedaviye dirençli 20 şizofreni hastalığı olan kişi ve yaş ve cin-siyet olarak uyumlu 20 sağlıklı kontrolde interlökin-4 (IL-4), transfor-ming growth faktör-? (TGF-?), myeloperoksidaz (MPO) ve nükleer faktör-?B aktivasyonunun (NF-?B) plazma düzeyleri analiz edildi. Hastalık şiddeti Kısa Psikiyatrik Değerlendirme Ölçeği kullanılarak de-ğerlendirildi (BPRS).Bulgular: Bu çalışmada antipsikotik tedaviye dirençli şizofreni hasta-larında serum TGF-? düzeyleri kontrollere göre anlamlı derecede daha düşük, NF-?B düzeyleri ise anlamlı derecede daha yüksek saptandı. Se-rum IL-4 ve MPO düzeylerinde ise hasta ve kontrol grupları arasında anlamlı fark bulunmadı.Sonuç: Bu çalışmada dirençli şizofreni hastalarında, psikotik belirtilerin alevli olduğu dönemde TGF-? seviyesinin düşük saptanması, Th1/Th2 dengesini sağlamakta yetersiz kaldığını göstermektedir. Bu durumun şi-zofrenide dirençten sorumlu olup olmadığının araştırılması için geniş ölçekli çalışmalara ihtiyaç vardır. Önceki çalışmalarda ilk atak tedavisiz şizofreni hastalarında gösterilen NF-?B deki yükselmenin, bu çalışmada tedaviye dirençli şizofreni hastalarında da gösterilmiş olması NF-?B'nin hastalığın fizyopatolojisine baştan beri dahil olduğunu düşündürmek-tedir.

🔖

Cite This Article

KARTALCI, Ş., ERBAY, L. G., ZAYMAN, E. P., OTLU, Ö., KARABULUT, A. B., KARTALCI, G. (2016). IL-4, TGF-?, NF-?B and MPO levels in Patients with Treatment Resistant Schizophrenia. Türk Psikiyatri Dergisi, Cilt: 27 - Sayı: 3, 170–175. https://ajindex.com/articles/88250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Abbas AK, Lohr J, Knoechel B (2007) Balancing autoaggressive and protective T cell responses. J Autoimmun 28:59-61.
  2. Abu-Soud HM, Hazen SL (2000) Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275:5425-30.
  3. Albensi BC, Mattson MP (2000) Evidence for the involvement of TNF and NF- kappaB in hippocampal synaptic plasticity. Synapse 35:151-9.
  4. Altamura AC, Boin F, Maes M (1999) HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. Eur Neuropsychopharmacol 10:1-4.
  5. Anderson G, Berk M, Dodd S ve ark. (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:1-4.
  6. Baeuerle PA (1991) The inducible transcription activator NF-kappa B: Regulation by distinct protein subunits. Biochim Biophys Acta 1072:63- 80. Brenner H, Merlo M (1995) Definition of therapy-resistant schizophrenia and its assessment. Eur Psychiatry 1:11-17.
  7. Brown AS, Patterson PH (2011) Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 37:284-90.
  8. Curfs JH, Meis JF, Hoogkamp-Korstanje JA (1997) A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev 10:742-80.
  9. Dean OM, Van Den Buuse M, Bush AI ve ark. (2009) A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 16:2965-76.
  10. Drexhage RC, Knijff EM, Padmos RC ve ark. (2010) The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10:59-76.
  11. Fan X, Goff DC, Henderson DC (2007) Inflammation and schizophrenia. Expert Rev Neurother 7:789-96.
  12. Gallin JI, Snyderman R, Haynes BF ve ark. (1999) Inflammation: Basic Principles and Clinical Correlates. 3rd Edition.
  13. New York, Lippincott Williams & Wilkins, 1360 pp. Gutierrez H, Davies AM (2011) Regulation of neural process growth, elaboration and structural plasticity by NF-?B. Trends Neurosci 34:316-25.
  14. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68.
  15. Hope S, Ueland T, Steen NE ve ark. (2013) Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizop